Full Picture

Article analysis:

The article is overall reliable and trustworthy, as it provides a comprehensive overview of colorectal cancer, neoadjuvant chemoradiotherapy, and metabolomics as a tool to predict therapeutic toxicities and responses in patients with rectal cancer. The article cites relevant studies to support its claims, such as clinical statistics showing that only 10–35% patients can achieve pathological complete response after nCRT treatment, multicenter randomized phase III study showing that up to 20–36% LARC patients who received nCRT treatments presented with preoperative grade 3–4 toxic effects, etc. The article also mentions potential biases such as interpatient variability of adverse events commonly present in LARC patients treated with nCRT, sex-specific differences in grade 3–4 diarrhea, stomatitis, and alopecia due to FOLFIRI treatment, etc., which are important points of consideration when evaluating the efficacy of nCRT treatments. However, there are some missing points of consideration that could have been explored further such as potential risks associated with metabolomics analysis or possible counterarguments against using metabolomics for predicting therapeutic toxicities and responses in LARC patients. Additionally, the article does not provide any evidence for its claims regarding the efficacy of nCRT treatments or any promotional content related to this topic. Therefore, overall the article is reliable and trustworthy but could have included more information about potential risks associated with metabolomics analysis or possible counterarguments against using it for predicting therapeutic toxicities and responses in LARC patients.